Good and bad news for Cambridge kits
This article was originally published in Clinica
The US Bankruptcy Court has upheld Cambridge Biotech's licence under two patents issued to the Institut Pasteur for HIV-2 tests. However, it also ruled that Cambridge Biotech's HIV-1 Western blot confirmatory test infringes a third patent issued to the Institut Pasteur and so prevents the company from manufacturing and selling it. The latter test accounted for less than 15% of the company's diagnostic revenue in 1994, says Cambridge, which says it will appeal the decision.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.